405230-95-7

Upstream product

• 6256-96-8 3,4-diamino-2,5,6-trifluoropyridine 
• 405230-83-3 4-nitramino-2,3,6-trifluoropyridine 
• 1735-84-8 3-chloro-2,4,5,6-tetrafluoropyridine 
• 2693-57-4 4-amino-3-chloro-2,5,6-trifluoropyridine 
• 63489-55-4 4-Amino-2,3,6-trifluoropyridine 
• 405231-20-1 1-[(1-acetyloxy-1-ethoxy)methyl]-4,6,7-trifluoroimidazo[4,5-c]pyridine 
• 14036-06-7 diethoxymethyl acetate 
• 405230-88-8 4-amino-3-nitro-2,5,6-trifluoropyridine 

Downstream Products

• 405231-12-1 4,6,7-trifluoro-1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)imidazo[4,5-c]pyridine 
• 405231-13-2 4,6,7-trifluoro-3-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)imidazo[4,5-c]pyridine 

Relevant academic research and scientific papers

Novel nucleosides and related processes, pharmaceutical compositions and methods

The invention provides novel nucleosides and related processes, pharmaceutical compositions, and methods. The novel nucleosides are useful in a wide variety of antiviral, antineoplastic, and antibacterial applications. Preferred embodiments of the instant invention include novel 2 halogen-substituted, 3 halogen-substituted, and 2′,3′dihalogen-substituted analogues of 3-deazaadenosine, and novel 3 halogen-substituted analogues of 3-deazaguanosine. Compounds of the instant invention, including 4-Amino-6-fluoro-1-(β-D-ribofuranosyl)imidazo[4,5-c]pyridine and 6-Amino-7-bromo-1,5-dihydro-1-β-D-ribofuranosylimidazo[4,5-c]pyridin-4-one, have exhibited potent antiviral and anticancer activity in vitro. The compounds are also useful in the concomitant treatment of bacterial infections associated with viral infections such as AIDS.

Synthesis of halogen-substituted 3-deazaadenosine and 3-deazaguanosine analogues as potential antitumor/antiviral agents

Various 2-halogen-substituted analogues (38, 39, 43 and 44), 3-halogensubstituted analogues (51 and 52), and 2′,3′ -dihalogen- substituted analogues (57-60) of 3-deazaadenosine and 3-halogen-substituted analogues (61 and 62) of 3-deazaguanosine have been synthesized as potential anticancer and/or antiviral agents. Among these compounds, 3-deaza-3-bromoguanosine (62) showed significant cytotoxicity against L1210, P388, CCRF-CEM and B16F10 cell lines in vitro, producing IC50 values of 3, 7, 9 and 7μM, respectively. Several 3-deazaadenosine analogues (38, 51, 57 and 59) showed moderate to weak activity against hepatitis B virus.